Journal of Investigative Dermatology Home

Estimating Cardiovascular Impacts of Drugs for Psoriatic Disease: A Long Way to Go

  • Stefan Siebert
    Correspondence: Stefan Siebert, Institute of Infection, Immunity & Inflammation, University of Glasgow, Sir Graeme Davies Building, 120 University Place, Glasgow G12 8TA, United Kingdom.
    Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
    Search for articles by this author
  • Naveed Sattar
    Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, United Kingdom
    Search for articles by this author
      Patients with psoriasis and psoriatic arthritis are at an increased risk of cardiovascular (CV) events. A recent systematic review and meta-analysis by González Cantero et al. (2021) evaluated the effects of biologics on CV imaging and biomarkers in patients with psoriasis. In this commentary, we discuss the clinical and management implications of these and the related results for patients with psoriatic disease and the need for further pharmacoepidemiological research.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      PDF Download and 24 Hours Online Access
      Society Members (SID/ESDR), remember to log in for access.


      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • D’Andrea E.
        • Vinals L.
        • Patorno E.
        • Franklin J.M.
        • Bennett D.
        • Largent J.A.
        • et al.
        How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools.
        BMJ Open. 2021; 11: e043961
        • Dixon W.G.
        • Watson K.D.
        • Lunt M.
        • Hyrich K.L.
        • British Society for Rheumatology Biologics Register Control Centre Consortium
        • Silman A.J.
        • et al.
        Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
        Arthritis Rheum. 2007; 56: 2905-2912
        • Kaptoge S.
        • Di Angelantonio E.
        • Lowe G.
        • Pepys M.B.
        • Thompson S.G.
        • et al.
        • Emerging Risk Factors Collaboration
        C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
        Lancet. 2010; 375: 132-140
        • Ferguson L.D.
        • Siebert S.
        • McInnes I.B.
        • Sattar N.
        Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions.
        Nat Rev Rheumatol. 2019; 15: 461-474
        • González-Cantero A.
        • Ortega-Quijano D.
        • Álvarez-Díaz N.
        • Ballester M.A.
        • Jiminez-Gomez N.
        • Jaen P.
        • et al.
        Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials.
        J Invest Dermatol. 2021; 141: 2402-2411
        • Hippisley-Cox J.
        • Coupland C.
        • Brindle P.
        Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.
        BMJ. 2017; 357: j2099
        • Jafri K.
        • Bartels C.M.
        • Shin D.
        • Gelfand J.M.
        • Ogdie A.
        Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study.
        Arthritis Care Res (Hoboken). 2017; 69: 51-57
        • Kitas G.D.
        • Nightingale P.
        • Armitage J.
        • Sattar N.
        • Belch J.J.F.
        • Symmons D.P.M.
        • et al.
        A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis.
        Arthritis Rheumatol. 2019; 71: 1437-1449
        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • MacFadyen J.G.
        • Chang W.H.
        • Ballantyne C.
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N Engl J Med. 2017; 377: 1119-1131
        • Roubille C.
        • Richer V.
        • Starnino T.
        • McCourt C.
        • McFarlane A.
        • Fleming P.
        • et al.
        The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
        Ann Rheum Dis. 2015; 74: 480-489
        • Sattar N.
        • Gill J.M.R.
        • Alazawi W.
        Improving prevention strategies for cardiometabolic disease.
        Nat Med. 2020; 26: 320-325
        • Taylor S.I.
        • Yazdi Z.S.
        • Beitelshees A.L.
        Pharmacological treatment of hyperglycemia in type 2 diabetes.
        J Clin Invest. 2021; 131: e142243

      Linked Article